Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
Authors:
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 12
Abstract
Cholangiocarcinoma (CCA) is a refractory cancer with limited treatment options and poorly understood molecular mechanisms underlying tumor development. The most effective treatment is surgical resection; however, patients are highly prone to recurrence. Moreover, considering that most patients are diagnosed in advanced stages, treatment options are restricted to palliative care, which results in poor prognosis. Due to the limited effect of chemotherapy and radiotherapy, targeted therapy is becoming a hot topic in the field of biliary cancer treatment. The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway involves a variety of key biological processes for cell survival, differentiation, and metabolism. Next-generation sequencing data mining has shown that high levels of FGF/FGFR expression are associated with reduced overall survival (OS) in CAA, which indicates that the FGF/FGFR pathway may be an effective target for CAA treatment. This paper reviews the effect of FGF/FGFR signaling on CCA from onset to treatment and highlights the promise of FGF/FGFR signaling pathway inhibitors for targeting CCA.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LSY19H160005)
- National Natural Science Foundation of China (81573003)
This publication has 69 references indexed in Scilit:
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant CancerCancer Discovery, 2013
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of CancerScience Translational Medicine, 2013
- Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer modelsBreast Cancer Research, 2013
- Basic fibroblast growth factor induces cholangiocarcinoma cell migration via activation of the MEK1/2 pathwayOncology Letters, 2011
- Risk factors for cholangiocarcinomaHepatology, 2011
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsAnnals of Oncology, 2010
- GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 SignalingCancer Research, 2010
- β-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast ThailandTropical Medicine & International Health, 2004